Life Science News

Naturally Splendid Enterprises Ltd. ("Naturally Splendid", "NSE" or "the Company") (FRANKFURT:50N)(TSXV:NSP)(OTC PINK:NSPDF) announces its unaudited financial results for the three months ended March 31, 2022. All amounts are in Canadian dollars and are prepared in accordance with International Financial Reporting Standards

During this reporting period, Covid-19 uncertainty negatively affected sales of existing product lines as well as impaired launches of new product lines. On March 11, 2020, the World Health Organization declared the outbreak of the novel coronavirus ("COVID-19") a global pandemic resulting in governments worldwide, including the Canadian government, enacting extensive measures in an effort to limit the spread of the virus. These measures, which include social distancing, travel restrictions, outright travel bans, and closures of non-essential businesses including restaurants, created a challenging period for the Company.

Naturally Splendid CFO Mr. George Ragogna stated "We are continuing to implement our strategic plan focused on plant-based opportunities. The Company is evolving the manufacturing capabilities and capacities of our existing certified food manufacturing facility as our product mix shifts to more plant-based entrees and appetizers from bars and bites. We have shifted our product mix due in large part to the ten (10) year Canadian exclusive manufacturing and distribution agreement that we executed with Australia's largest plant-based manufacturer, Flexitarian Foods. This agreement is renewable for a further ten (10) years. Naturally Splendid has also secured licensing rights from Flexitarian Foods for the exclusive use of the PlanteinTM trademark in Canada. With the PlanteinTM trademark now secured, we have completed all retail packaging and websites to support this brand. The Company has attended several trade shows recently to promote the launch of the PlanteinTM retail line and national distribution relationships have been formed with Canada's two largest distributors, Sysco Canada and Gordon Food Services (GFS)."

Mr. Ragogna adds, "The Company has completed the design and begun the re-purposing of our existing certified food manufacturing facility in Pitt Meadows, BC. All manufacturing equipment required to produce our plant-based entrees has been ordered with many significant components of the manufacturing line having already arrived at the Pitt Meadows facility. However, there have been delays in receiving some components required to complete the full build-out of the new production lines due to ongoing logistics challenges that much of the manufacturing industry continues to experience. We will continue to receive our plant-based inventories from Flexitarian Foods while the manufacturing lines are still being set up in our own facility. Once the new manufacturing lines in our facility are commissioned, the Company will see an almost immediate return by way of reducing product costs, and improved inventory control, resulting in an anticipated increase in margins. We look forward to providing updates in a timely manner." Naturally Splendid recorded a net loss and comprehensive loss of $747,787 for the three months ended March 31, 2022, compared to a net loss of $767,478 during the three months ended March 31, 2021. Gross profit margins increased by 29% of sales in the three months ended March 31, 2021, compared to the three months ended March 31, 2021, this is due to the increased profit margins in the new plant-based sales. The Company's sales decreased by approximately $160,000 from the comparative period. During the three-month period ended March 31, 2022, selling and distribution expenses decreased by approximately $35,000 largely due to a decrease in production (facility costs, quality assurance and lab testing).

Administrative expenses increased in 2022 compared to 2021 by $22,000. The increase was primarily due to an increase in office, rent and salaries and management and consulting and decreases were primarily due to bank charges and interest. Office rent and salaries reflect the cost of the production, warehouse, office and outside freezer storage premises, and corporate salaries, the increase was due to some employee severances and an increase in freezer storage, otherwise, the office, rent and salaries remained consistent. Management and consulting fees increased due to new consultants for the new plant-based product line.

Naturally Splendid recorded sales of $93,453 during the three months ended March 31, 2022, compared to $144,143 for the three months ended March 31, 2021. The Company's sales decreased by approximately $50,690 from the comparative period. During the three months ended March 31, 2022, the Company's sales decreased by approximately $160,000 from the comparative period. The Company had decreased sales in its private-label bars and bites business by approximately $71,000. Branded hemp products decreased by approximately $2,500 and its Natera Sport products decreased by approximately $101,000. The Company had sales of approximately $50,000 in its new Plant-based products. This is in line with the Company shifting its focus on the new plant-based entrees for contract manufacturing, private label and branded products and will continue to sell to the international Korean markets.

The cost of Sales during the three months ended March 31, 2022, was $54,463 compared to $221,587 in 2021. The Company's gross margin percentage is 41.7% of sales, during the three months ended March 3, 2022.

The Company continues to focus on its higher-margin products and new commercial opportunities for its new plant-based products. The bulk hemp seeds sold at a lower gross margin percentage than compared to plant-based products and private label sales. The Company is now focused. Gross profits for the three months ended March 31, 2022, were $38,990 (42% of sales) compared to $31,791 (13% of sales) for the three months ended March 31, 2021.


For the Three
Months Ended
March 31, 2022
For the Three
Months Ended
March 31, 2021

$

$

Statements of Loss Data
Revenue
93,453253,378
Cost of sales
(54,463)(221,587)
Gross Profit
38,99031,791
Selling and distribution expenses
(105,246)(140,166)
Administrative expenses
(681,531)(659,103)
Net income (loss)
(747,892)(743,636)
Basic and Diluted Earnings (Loss)
Per Share(0.00)(0.00)

About Naturally Splendid Enterprises Ltd.

Founded in 2010, NSE operates a food manufacturing facility just outside Vancouver, BC in Canada. The Company has established numerous healthy, functional foods under recognized brands such as Natera Sport™, Natera Hemp Foods, CHII, Elevate Me™ and Woods Wild Bar™, and most recently Natera Plant Based Foods, a line of delicious plant-based meat alternatives for the rapidly growing plant-based market segment. The Company has a myriad of new products and line extensions under development that are approaching launch. NSE, through its joint venture Plasm Pharmaceutical, has been approved for conducting a phase 2 clinical trial approved by Health Canada for treatment of COVID-19. NSE has also developed proprietary technologies for the extraction of high-demand, healthy omega 3 and 6 oils from hemp.

NSE contract manufacturers for healthy, functional food products and ingredients focusing on plant-based ingredients. The Company provides contract manufacturing services for many healthy food companies, private labeling a wide variety of nutritional food products destined for global healthy food markets.

For more information e-mail info@naturallysplendid.com or call Investor Relations at 604-5700902 (ext. 101)

On Behalf of the Board of Directors

Mr. J. Craig Goodwin
CEO, Director

Contact Information

Naturally Splendid Enterprises Ltd.
(NSP - TSX Venture; NSPDF - OTCQB; 50N - Frankfurt)
#108-19100 Airport Way
Pitt Meadows, BC, V3Y 0E2
Office: (604) 570-0902
Fax: (604) 465-1128
E-mail : info@naturallysplendid.com
Website: www.naturallysplendid.com

Forward-Looking Statements

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. Naturally Splendid cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond Naturally Splendid's control including, Naturally Splendid's ability to compete with large food and beverage companies; sales of any potential products developed will be profitable; sales of shelled hemp seed will continue at existing rates or increase; the ability to complete the sales of all bulk hemp seed purchase orders; and the risk that any of the potential applications may not receive all required regulatory or legal approval. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, Naturally Splendid undertakes no obligation to publicly update or revise forward-looking information.

NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

SOURCE: Naturally Splendid Enterprises Ltd.



View source version on accesswire.com:
https://www.accesswire.com/708042/Naturally-Splendid-Reports-First-Quarter-Results-for-2022

News Provided by ACCESSWIRE via QuoteMedia

NSP:CA
Naturally Splendid Enterprises

Naturally Splendid Enterprises


Keep reading...Show less
Naturally Splendid Reports Third Quarter Results for 2022 and Company Update

Naturally Splendid Reports Third Quarter Results for 2022 and Company Update

Naturally Splendid Enterprises Ltd. ("Naturally Splendid", "NSE" or "the Company") (FRANKFURT:50N)(TSXV:NSP)(OTC PINK:NSPDF) announces its unaudited financial results for the nine months ended September 30, 2022. All amounts are in Canadian dollars and are prepared in accordance with International Financial Reporting Standards

Naturally Splendid CEO Mr. Craig Goodwin states, "As we continue to focus our efforts and resources on PlanteinTM Plant-Based Foods and our ten (10) year exclusive manufacturing and distribution agreement with Flexitarian Foods PTY Ltd., there have been many positives as well as a number of challenges. The positives include our recent launch into retail, and the return to trade shows where are products have been getting exceptional reviews, as well as our expanding relations with our national distributors. However, the Company has experienced significant challenges as well, the most notable being the continued delay of customized manufacturing lines being assembled in Shanghai, China. The delay to date has been due to a combination of shortage of computer chips, combined with on-going Covid challenges and subsequent quarantining in Shanghai".

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Naturally Splendid Management Update

Naturally Splendid Management Update

Naturally Splendid Enterprises Ltd. ("Naturally Splendid", "NSE" or "the Company") (FRANKFURT:50N)(TSXV:NSP)(OTC PINK:NSPDF) announces that Mr. George Ragogna will be stepping down as CFO and a Member of the Board of Directors effective immediately

Mr. Ragogna will remain with the Company as an Independent Consultant, focusing his efforts on logistics and our inventory management control system. Mr. Bryan Carson, current Executive VP and Company Co-founder, will step in as interim CFO.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Naturally Splendid Presents at Grocery Innovations Canada Trade Show in Toronto

Naturally Splendid Presents at Grocery Innovations Canada Trade Show in Toronto

Naturally Splendid Enterprises Ltd. ("Naturally Splendid", "NSE" or "the Company") (FRANKFURT:50N)(TSXV:NSP)(OTC PINK:NSPDF) is pleased to announce the Company presented the PlanteinTM line of plant-based entrees at the Grocery Innovations Canada trade show on October 25 and October 26, 2022, at the Toronto Congress Centre

Grocery Innovations Canada, is one of Canada's premier grocery trade show events, bringing together manufacturers and retailers from not only Eastern Canada, but in fact from all across the country. Naturally Splendid featured the PlanteinTM line of plant-based products to retailers and distributors from across the country.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Vegan Supply to Distribute Plantein Through Foodservice Network & Sell in Retail Store

Vegan Supply to Distribute Plantein Through Foodservice Network & Sell in Retail Store

VANCOUVER, BC / ACCESSWIRE/ September 6, 2022 / Naturally Splendid Enterprises Ltd.("Naturally Splendid", "NSE" or "the Company") (FRANKFURT:50N)(TSXV:NSP)(OTC Pink:NSPDF) is pleased to announce that Vegan Supply will carry a selection of PlanteinTM products for its retail and foodservice customers.

Vegan Supply, a Vancouver based company with both retail and foodservice distribution, began business in 2015 as the world's largest e-commerce marketplace exclusively providing their retail customers and foodservice clients with high-quality vegan products. Vegan Supply is listing five (5) PlanteinTM plant-based entrees: Nuggets, Schnitzel, Crumbed Tenders, Sweet Chili Tenders, and Crispy Burgers. The PlanteinTM line of products will be available through Vegan Supply's retail store in Vancouver, BC, their e-commerce platform, and marketed to their foodservice distribution network.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
CORRECTION: Naturally Splendid Reports Second Quarter Results for 2022

CORRECTION: Naturally Splendid Reports Second Quarter Results for 2022

This release acts as a correction for the release posted on 8/29/2022 at 10:30 PM EDT from Naturally Splendid Enterprises Ltd. announcing its second quarter results for 2022 due to an error in comments stated

Naturally Splendid Enterprises Ltd. ("Naturally Splendid", "NSE" or "the Company") (FRANKFURT:50N)(TSXV:NSP)(OTC PINK:NSPDF) announces its unaudited financial results for the six months ended June 30, 2022. All amounts are in Canadian dollars and are prepared in accordance with International Financial Reporting Standards

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Small Cap Growth Virtual Investor Conference: Presentations Now Available for Online Viewing

Small Cap Growth Virtual Investor Conference: Presentations Now Available for Online Viewing

Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from its Small Cap Growth Virtual Investor Conference held on December 1 st are now available for online viewing.

REGISTER NOW AT : https://bit.ly/3H26Z7H

The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download
investor materials from the company's resource section.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Graphene Manufacturing Group Announces Closing of $5.7M Bought Deal Offering

Graphene Manufacturing Group Announces Closing of $5.7M Bought Deal Offering

Graphene Manufacturing Group Ltd. (TSXV: GMG) ("GMG" or the "Company") is pleased to announce that the Company closed its previously announced bought deal prospectus offering of units (the "Units") of the Company, including exercise in full of the over-allotment option (the "Offering"). A total of 2,091,850 Units were sold at a price of C$2.75 per Unit (the "Offering Price") for gross proceeds of approximately C$5.75 million.

Each Unit is comprised of one ordinary share in the capital of the Company (each, an "Ordinary Share") and one Ordinary Share purchase warrant (each, a "Warrant"). Each Warrant entitles the holder to purchase one Ordinary Share at a price of C$3.35, at any time until November 30, 2026. The Offering was completed pursuant to an underwriting agreement dated November 14, 2022 among the Company and Eight Capital, as lead underwriter and sole bookrunner, and a syndicate of underwriters including Raymond James Ltd., H.C. Wainwright & Co., LLC, Leede Jones Gable Inc., PI Financial Corp., and Research Capital Corporation (collectively, the "Underwriters").

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
IPA's Subsidiary BioStrand and BriaCell Announce Artificial Intelligence Collaboration and License Agreement to Discover and Develop Anti-Cancer Antibodies

IPA's Subsidiary BioStrand and BriaCell Announce Artificial Intelligence Collaboration and License Agreement to Discover and Develop Anti-Cancer Antibodies

IPA (IMMUNOPRECISE ANTIBODIES LTD.) ( "IPA") (NASDAQ: IPA), an advanced biotherapeutic research and technology company, today announced that BioStrand BV ("BioStrand"), an AI in silico discovery subsidiary of IPA, has entered into a research collaboration and license agreement (the "Agreement") with BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) (TSX: BCT) ("BriaCell"), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221130005423/en/

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Greenlane Renewables Announces Dairy RNG System Sales Contract

Greenlane Renewables Announces Dairy RNG System Sales Contract

~Greenlane to supply a biogas upgrading system for a new project in the Western U.S.~

 Greenlane Renewables Inc. (" Greenlane ") (TSX: GRN) (FSE: 52G) is pleased to announce that its wholly-owned subsidiary, Greenlane Biogas North America Ltd., has been awarded a $4.6 million ( US$3.5 million ) contract for a dairy RNG project in the Western United States for the supply of a biogas upgrading system. Greenlane will supply its pressure swing adsorption system for upgrading biogas generated from anaerobic digestion of dairy cow manure into carbon negative renewable natural gas ("RNG") suitable for injection into the local pipeline network. Order fulfillment is expected to commence immediately.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Nanalysis Reports Third Quarter 2022 Results

Nanalysis Scientific Corp. ("the Company") (TSXV: NSCI) (OTCQX: NSCIF) (FRA: 1N1), a leader in portable NMR machines and MRI technology for healthcare and industrial applications, releases its second quarter results ending September 30, 2022. Chief Executive Officer, Sean Krakiwsky and Interim Chief Financial Officer, Randall McRae will host a conference call at 5 P.M. Eastern Time today to discuss the results. A second call will be held for European investors at 8:30am ET on Wednesday, November 30 th . All interested parties are invited to join these calls.

Nanalysis Scientific Corp. (CNW Group/Nanalysis Scientific Corp.)

"I am pleased to report we have returned to our strong growth trajectory in the third quarter," said Sean Krakiwsky, Founder and CEO of Nanalysis. "We continue to focus on growing all segments of our organization and executing on our operational strategy. In the third quarter we laid significant groundwork on our previously announced multi-year airport security contract with the Canadian Air Transportation Security Authority and have now begun operations on that project in the fourth quarter. We believe we have also resolved the issues that slowed our growth in our benchtop NMR sales organization in the second quarter, returning to strong benchtop NMR sales figures. We expect to see continued strength in our business in the fourth quarter, which has historically been a strong quarter for our business."

Financial highlights (unaudited) for the three months ended September 30, 2022:

  • For the three months ended September 30, 2022 , the Company reported consolidated revenue of $6,878K , an increase of $3,542K or 106% from the comparative period in 2021. This includes $6,145K in product sales and $733K of service revenue related to airport security services.
  • Gross margin on total sales was 43% for the three months ended September 30, 2022 . This was the result of increased training costs of personnel for the CATSA airport security project, increased personnel and training in Nanalysis' manufacturing group to increase manufacturing capacity, an increase in costs due to worldwide supply chain constraints and inflation, as well as a specific medical imaging project in our RS2D subsidiary that had lower than normal gross margins. Management expects margins to improve as continued investments in manufacturing improvements continue, sales levels increase, and the CATSA airport security project continues to phase-in to full capacity.
  • (Loss) Income before other items for the three months ended September 30, 2022, was $( 618K ) versus $12K compared to the same period last year.
  • Net loss for the three months ended was $(2,599K), as compared to the three-month loss for September 30, 2021, of $(857K).
  • The Company had cash on hand of $7,925K, an undrawn credit facility of $6,734K, working capital of $9,658K and an undrawn government contribution funding of $4,985K as of September 30, 2022.

Recent strategic and operational highlights during and subsequent to the second quarter of 2022 include:

  • Funding received from Prairies Economic Development Canada: Subsequent to September 30, 2022 , the Company received its first $1.5 million in funding from the Business Scale-up Program. This program will provide Nanalysis up to $4,985K of funding in the form of an unsecured interest free loan. The program is designed to help fast growing tech firms scale-up and enter new markets.
  • Consolidation of credit facility: On November 18, 2022 , the Company closed a credit line with a major Canadian bank, consolidating its existing operating facilities into a $9 million operating line.  The line bears interest at a rate of prime plus 0.65% and will allow the Company to execute on its growth and expansion plans.
  • Security Service : In November 2022 , the Company began providing services under the CATSA airport security contract and continues to execute successfully on its phase-in plan for the entire project.
  • Manufacturing : In addition to Nanalysis investing in a state of the art five axis machining centre and wire electrical discharge machine in the second quarter of 2022, Nanalysis has also invested in growing out the manufacturing team allowing the Company to meet expected growth in demand as it heads into 2023.
  • Quad Systems : The company has seen continued development with Quad System's full high-field NMR product. Module sales have continued to increase in the third quarter and the Company expects material revenue from the acquisition in 2023.
Operating Results

For the nine months ended September 30, 2022 , the Company reported consolidated revenue of $17,618K , an increase of $6,664K or 61% from the comparative period in 2021. The increase from Q3 2021 can be attributed to continued increases in shipments of the 100MHz benchtop NMR unit, coupled with revenue from the recent acquisition, K'Prime, offset by lower RS2D revenue than in Q3 2021.

Gross profit for the nine months ended September 30, 2022 , was $9,504K (a margin of 54%) compared to gross profit of $7,152K (a margin of 65%) for the nine months ended September 30, 2021 . Margins for the nine months ended September 30, 2022 , decreased over the nine months ended September 30, 2021 , as a result of increased component costs because of world-wide supply chain challenges, low margins on a specific Q3 project in RS2D, training costs included in cost of services related to the CATSA airport security project phase in, and investments made in the Company's manufacturing workforce beginning in the second quarter.

The Company's net loss for the nine months ended was $(6,623K) , as compared to the nine-month loss for the period ended September 30, 2021 , of $(1,127K) . The increased loss was due to higher sales and marketing expenses, increased general and administration expenses and increased research and development expenses, both in the Nanalysis segment and from the new acquisitions. In addition, there were business acquisition costs from the two transactions completed, increased depreciation and amortization expense, and increased finance expenses partially offset by no RS2D earnout in the quarter and increased revenues.

Outlook

"Our main objective continues to be focusing on executing our business plan, including ramping up sales of our 100 MHz product, completing the roll out of the CATSA airport service contract, and capitalizing on business opportunities brought by our recent acquisitions. We have successfully restructured and refocused our benchtop NMR salesforce and expect growing demand in 2023 for benchtop products, and we continue to work towards the launch of a full multi-module high-field NMR product via Quad Systems," said Sean Krakiwsky .

"With a slower second quarter well behind us, we have returned to our high growth trajectory and continue to have confidence that Nanalysis is well positioned for solid growth in 2023 and the years to come. Operational excellence remains our mantra, as we will continue to leverage existing customer relationships, our innovative technologies, and a motivated and professional team to fuel growth. We are confident that we will deliver the value we've created by our recent acquisitions to our shareholders through the remainder of 2022 and into the new year," concluded Mr. Krakiwsky.

Conference Call

Investors interested in participating on the live call can dial 1-888-664-6392 or 416-764-8659 from abroad. Investors can also access the call online through a listen-only webcast here:
https://app.webinar.net/JoLVkw4jEmX or on the investor relations section of the Company's website HERE . The webcast will be archived on the Company's investor relations webpage for at least 90 days and a telephonic playback will be available for seven days after the conference call by calling 1-888-390-0541 or 416-764-8677, conference ID # 833132.

Additionally, the Company will be hosting a Q&A session for it's European investors tomorrow, Wednesday, November 30 th at 8:30am ET which can be accessed by the following link: : Click here to join the meeting , or call in (audio only) +1 437-703-4522, Phone Conference ID: 295 204 525#.

About Nanalysis Scientific Corp. (TSXV: NSCI, OTCQX: NSCIF, FRA:1N1)

Nanalysis trades on the TSX Venture Exchange (TSXV) in Canada with ticker symbol 'NSCI', OTC and the Frankfurt exchange under the ticker symbol '1N1'. The company's business is what we term "MRI and NMR for industry". The company develops and manufactures portable Nuclear Magnetic Resonance (NMR) spectrometers or analyzers for laboratory and industrial markets. The NMReady-60™ was the first full-feature portable NMR spectrometer in a single compact enclosure requiring no liquid helium or any other cryogens. The Company has followed up that initial offering with new products and continues to have a strong innovation pipeline. Nanalysis began selling a 100MHz device in 2020. The Company's new device is the most powerful and most advanced compact NMR device ever brought to market.  Nanalysis devices are used in many industries (oil and gas, chemical, mining, pharma, biotech, flavor and fragrances, agrochemicals, law enforcement, and more) as well as numerous government and university research labs around the world. The Company continues to exploit new global market opportunities independently and with partners.

With the recent acquisition of K'Prime, the Company maintains a North American sales and service company of over 40 individuals who cover scientific instrumentation for pharma, food, chemical and oil & gas customers, as well as imaging systems and services for security applications.  Additionally, the Company has a 43% ownership in Quad Systems AG ("Quad Systems"), with an option to purchase the remaining shares.  Quad Systems is a Zurich-based Nuclear Magnetic Resonance ("NMR") company focused on high-field NMR for pharmaceutical and other vertical markets.

Notice regarding Forward Looking Statements and Legal Disclaimer

This news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "anticipates", "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed", "positioned" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

Neither TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/nanalysis-reports-third-quarter-2022-results-301689459.html

SOURCE Nanalysis Scientific Corp.

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/November2022/29/c7594.html

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Avricore Health Reports Third-Quarter 2022 Results

Avricore Health Reports Third-Quarter 2022 Results

Avricore Health INC. (TSXV: AVCR) (the " Company " or " AVCR ") today released its Q3 results which demonstrate significant revenue growth, indicating it can scale sustainably and deliver on its long-term objectives.

The Company's objective to create the world's first cloud-connected point-of-care network in community pharmacy is on track to becoming a reality, bringing powerful health screening and data management tools to community pharmacies and ensuring better outcomes for patients.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×